FDA grants EUA to Invivyd’s PEMGARDA for COVID-19 pre-exposure prophylaxis in immunocompromised individuals
Invivyd, Inc. (Nasdaq: IVVD), a pioneering biopharmaceutical company dedicated to safeguarding vulnerable populations from severe viral infectious diseases, has recently made headlines with the announcement of the U.S. Food and Drug Administration (FDA) granting Emergency Use Authorization (EUA) for PEMGARDA (pemivibart). This groundbreaking treatment, formerly known as VYD222, is a half-life extended monoclonal antibody (mAb) […]